Journals / Osteoporoz Dünyasından / 2005 / Cilt: 11 - Sayı: 2

Osteogenesis imperfecta presented with vertebral fractures after pregnancy and treatment with cyclical etidronate: A case report

Gebelik sonrası vertebral kırıklarla ortaya çıkan osteogenezis imperfekta ve siklik etidronat tedavisi: Olgu sunumu

Pages
85–88
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the best treatment regimen and the long-term outcomes of etidronate therapy are unknown.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Osteogenesis imperfecta(OI) is a kongenital skelatal disorder charecterized by low bone mass and increased bone fragility.
📊
Key Findings & Data:Fractures due to increased bone fragility occur frequently in childhood and decrease with age.
💡
Conclusion & Impact:However, the best treatment regimen and the long-term outcomes of etidronate therapy are unknown.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Osteogenezis imperfekta · Gebelik · Etidronik asit

Abstract

Osteogenesis imperfecta(OI) is a kongenital skelatal disorder charecterized by low bone mass and increased bone fragility. Fractures due to increased bone fragility occur frequently in childhood and decrease with age. Only a few studies have been reported regarding the teratment of adult patients with OI. Our case was a 27 year old woman with severe back pain occured when she was lifting her baby. The patient had experienced multiple fractures of long bones by her childhood. Compression fractures at thoracal 10 and 12 vertebrae were found on Magnetic Resonance Imaging . Dual energy X-ray absorptiomety(DEXA) showed that markedly decreased bone mineral density(BMD) both at lumbar spine and femur. The diagnosis of OI type I was based on the findings of blue sclera, antecedent multiple fractures, positive family history and low bone mass. Patient was treated with cyclical etidronate, calcium and Vitamin D over a year. No new fractures were observed during the treatment period. Lomber and proximal femur BMD’s were found to be significantly increased at the end of one year. Our case was treated succesfully with combination of cyclical etidronate, calcium and vitamin D. Etidronate would seem to be available treatment for adult patients with OI. However, the best treatment regimen and the long-term outcomes of etidronate therapy are unknown.

Özet

Osteogenesis imperfekta(Oİ) düşük kemik kütlesi ve artmış kemik kırılganlığı ile karakterize konjenital bir iskelet bozukluğudur.Artmış kemik kırılganlığı nedeniyle kırıklar sıklıkla çocukluk çağında ortaya çıkar ve yaş ile azalır. Erişkin Oİ’lı hastaların tedavisine dair sadece birkaç çalışma bildirilmiştir. Olgumuz bebeğini kaldırırken ciddi sırt ağrısı ortaya çıkan 27 yaşında kadın hastaydı. Hasta çocukluğunda çok sayıda uzun kemik kırığı geçirmişti. Manyetik Rezonans Görüntülemede torakal 10 ve 12. vertebralarda kompresyon kırıkları tespit edildi. Dual Energy X-Ray Absorbtiometry (DEXA) hem femur hem de omurgada belirgin şekilde düşük kemik mineral yoğunluğu’nu (KMY) gösterdi. Mavi sklera, geçirilmiş çok sayıda kırık, pozitif aile öyküsü ve düşük kemik kütlesi temel alınarak hastaya Osteogenesis imperfekta Tip I tanısı konuldu. Hasta siklik etidronat, kalsiyum ve vitamin D ile bir yılı aşkın süre tedavi edildi. Tedavi süresince yeni kırık gözlenmedi. Bir yıl sonunda bel ve proksimal femur KMY’ğu anlamlı derecede artmış olarak tespit edildi. Hastamız siklik etidronat, kalsiyum ve vitamin D kombinasyonu ile başarılı bir şekilde tedavi edilmiştir.Etidronat adult Oİ hastarında kullanılabilir bir tedavi gibi gözükmektedir. Bununla beraber etidronat tedavisi için en iyi tedavi rejimi ve uzun dönem sonuçları bilinmemektedir.

🔖

Cite This Article

BAHADIR, C., KORKMAZ, Ö., ŞAHİN, Z. (2005). Osteogenesis imperfecta presented with vertebral fractures after pregnancy and treatment with cyclical etidronate: A case report. Osteoporoz Dünyasından, Cilt: 11 - Sayı: 2, 85–88. https://ajindex.com/articles/286776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Preckop DJ, Kuivaniemi H.Disorders of intermediary metabolism. Harrison's Principles of Internal Medici- ne. ln:Braunwald E, Fauci AS,Kasper DL, Hauser Si, Long DL, Lameson JL, ed. New York, McGraw Hill. 2001:2345-2320
  2. Shapiro JR,Rowe D.Heritable disorders of structure proteins. Kelley's Textbook of Rheumatology. InJr.Harris ED,Budd RC, Genovese MC, Firestein GS, Sargent JS, Sledge CB, Ruddy Ş ad. Pensylva- nia, Elsewier Saunders 2000:1547-1560
  3. DiMeglio LA, Ford L, McClintock C et al. Intraveno- us pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.Bone 2004:35(5):1038-45
  4. Grissom LE, Kecskemethy HH, Bachrach SJ et al. Bone densitometry in pediatric patients treated with pamidronate.Pediatr Radiol 2005:18;156-61
  5. Adıyaman P, Ocal G, Berberoglu M, et al. The clini- cal and radiological assessment of cyclic intraveno- us pamidronate administration in children with oste- ogenesis imperfecta. Turk J Pediatr. 2004:46(4): 322-8
  6. Zeitlin L, Rauch F, Plotkin H et al. Height and weight development during four years of therapy with cycli- cal intravenous pamidronate in children and adoles- cents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003:111(5 Pt 1):1030-6 7. Arikoski P, Silverwood B, Tillmann Vetal. Intraveno- us pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of in- dices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.Bo- ne 2004:34(3):539-46 8. Dimeglio LA, Ford L, McClintock C et al. Compari- son of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005:18(1):43-53
  7. Adami S, Gatti D, Colapietro F et al. Intravenous ne- ridronate in adults with osteogenesis imperfecta.J Bone Miner Res. 2003:18(1):126-30
  8. Iwamoto J, Takeda T, Sato Y. Effect of treatment with alendronate in osteogenesis imperfecta type I: a ca- se report. Keio J Med. 2004:53(4):251-5
  9. Iwamoto J, Takeda T, Ichimura S et al. Effects of cycli- cal etidronate with alfacalcidol on lumbar bone mine- ral density, bone resorption, and back pain in postme- nopausal women with osteoporosis. J Orthop Sci 2003:8(4):532-7.